Carevive software for Kidney Cancer

Phase-Based Progress Estimates
Kidney CancerCarevive software - Other
All Sexes
What conditions do you have?

Study Summary

This trial will test if a software that monitors treatment-related side effects and creates self-care management plans for these symptoms is feasible to implement among patients with metastatic renal cell carcinoma. Additionally, it will collect preliminary data on treatment-related side effects, quality of life, distress level, and drug adherence.

Eligible Conditions
  • Kidney Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

4 Primary · 5 Secondary · Reporting Duration: 48 weeks

48 weeks
Average Usability Score Using the Software Usability Scoring System
Carevive Survey Usage Rates
Clinician Reported Toxicities Using CTCAE
Distress Level Using the NCCN Distress Thermometer
Patient Reported Toxicities Using PRO-CTCAE Questions
Quality of Life Determination Using the FKSI-DRS Survey
Reasons Participants Do Not Complete Survey or Utilize Care Plans
Reasons for Declining Study Participation
• Health Care Utilization Assessment By Quantification of Health Care Visits or Hospitalizations

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Use of Carevive software
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Carevive software · No Placebo Group · N/A

Use of Carevive software
Experimental Group · 1 Intervention: Carevive software · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

University of RochesterLead Sponsor
791 Previous Clinical Trials
501,699 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are literate in the English language.
You have histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease.
You are at least 18 years of age.